Royalty Pharma RPRX Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on trailing twelve months.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's return on equity?
- Royalty Pharma (RPRX) reported return on equity of 8.4% in Q1 2026.
- How has Royalty Pharma's return on equity changed year-over-year?
- Royalty Pharma's return on equity decreased by 24.6% year-over-year, from 11.1% to 8.4%.
- What is the long-term trend for Royalty Pharma's return on equity?
- Over 2 years (2021 to 2025), Royalty Pharma's return on equity has grown at a -23.8% compound annual growth rate (CAGR), from 64% to 37.2%.
- What does return on equity mean?
- How much profit the company earns on the money shareholders have invested.
- How do you interpret return on equity?
- Higher is better, but very high ROE can be manufactured by leverage — a thin equity base inflates the ratio. Read it next to debt-to-equity and ROIC to tell genuine returns from balance-sheet engineering.
- How does return on equity compare across companies?
- Comparable across peers, with the leverage caveat. Negative or near-zero equity makes ROE meaningless, so it is suppressed there.